Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiPASS: PSMA PET Combined With MRI Compared to SOC for Detection of Prostate Cancer
NCT07052214Phase 3Active, not recruiting
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Modality
- Peptide-Drug Conjugates
- Countries
- 2
01
Overview
A Phase 3 trial of TLX007-CDx in prostate cancer (PCa), sponsored by Telix Pharmaceuticals Limited. Started Aug 2025; status: active, not recruiting.
02
Drugs
TLX007-CDx
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07052214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052214.